Abstract
Background Treatment with PD-(L)1 blocking agents has demonstrated durable efficacy in advanced NSCLC, but only in a minority of patients. Multiple biomarkers for predicting treatment benefit have been investigated, but their combined performance has not been extensively studied. Here, we assess the combined predictive performance of multiple biomarkers in a series of NSCLC patients treated with nivolumab.
Methods Pretreatment samples from 135 patients treated with nivolumab were used to assess the predictive performance of CD8 tumor-infiltrating lymphocytes (TILs), intratumoral (IT) localization of CD8 TILs, PD-1 high expressing TILs (PD1T TILs), CD3 TILs, CD20 B-cells, tertiary lymphoid structures (TLS), PD-L1 tumor proportion score (TPS) and the Tumor Inflammation score (TIS). Patients were assigned to a training (n=55) and validation set (n=80). The primary outcome measure was Disease Control at 6 months (DC 6m) and the secondary outcome measure was DC at 12 months (DC 12m).
Results In the validation cohort, the two best performing composite biomarkers (i.e. CD8+IT-CD8 and CD3+IT-CD8) demonstrated similar or lower sensitivity (64% and 83%) and NPV (76% and 85%) than the individual biomarkers PD-1T TILs and TIS (sensitivity: 72% and 83%, NPV: 86% and 84%) for DC 6m, respectively. Also, at 12 months, both selected composite biomarkers (CD8+IT-CD8 and CD8+TIS) showed less predictive performance compared to PD-1T TILs and TIS alone. PD-1T TILs and TIS showed high sensitivity (86% and 100%) and NPV (95% and 100%) for DC 12m. PD-1T TILs could better discriminate patients with no long-term benefit, since specificity was substantially higher as compared to TIS (74% versus 39%).
Conclusion Composite biomarkers did not show improved predictive performance compared to PD-1T TILs and TIS alone for both the 6- and 12-months endpoint. PD-1T TILs and TIS identified patients with DC 12m with high sensitivity. Patients with no long-term benefit to PD-1 blockade were most accurately identified by PD-1T TILs.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: E.F.S. reports financial compensation to the institution for attendance of advisory boards and speaker engagements from AstraZeneca, Bristol Myers Squibb, Bayer, DSI, Eli Lilly, MSD, Merck, Novartis, Pfizer, Takeda, Regeneron, Roche Genentech, Roche Diagnostics, Boehringer Ingelheim, Sanofi. Research support from Astra Zeneca, Bristol Myers Squibb, Merck, MSD. All are outside the submitted work. GA Meijer is co-founder and board member (CSO) of CRCbioscreen BV, CSO of Health-RI (Dutch National Health Data infrastructure for research & innovation), and member of the supervisory board of IKNL (Netherlands Comprehensive Cancer Organisation). He has a research collaboration with CZ Health Insurances (cash matching to ZonMw grant) and he has research collaborations with Exact Sciences, Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics (PGDX), DELFi and Hartwig Medical Foundation these companies provide materials, equipment and/or sample/genomic analyses. All are outside the submitted work. K.M. reports grants from AstraZeneca, non-financial support from Roche, Takeda, Pfizer, PGDx and DELFi, speakers fee from MSD, Roche, AstraZeneca, Benecke and consultant fee from Pfizer, BMS, Roche, MSD, Abbvie, AstraZeneca, Diaceutics, Lilly, Bayer, Boehringer Ingelheim and Merck outside the submitted work. K.H., V.N, M.M, R.D.S., M.M.H, D.S.T. have nothing to disclose.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all patients for research usage of material not required for diagnostic use by institutionally implemented opt-out procedure.The study was conducted in accordance with the Declaration of Helsinki. The data was accessed for research purposes after the approval of the Institutional Review Board (IRB) of the Netherlands Cancer Institute on January 11, 2018 (CFMPB586).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
